Advancements in Nanocarriers for Targeted Drug Delivery in Pharmaceutics

*Amit Khanna, ¹Shivam Sharma
*Research Scholar, Rajasthan Pharmacy College, Jaipur
¹Assistant Professor, Rajasthan Pharmacy College, Jaipur

Unveil Article Specifications

Authors: Amit Khanna, Shivam Sharma

Journal: Pexacy International Journal of Pharmaceutical Science

Volume/Issue: Volume 2, Issue 5

Page Range: 45-53

Publication Date: 28/05/2023

Contact: khannaamit90@gmail.com

Abstract- Nanocarriers have emerged as a transformative technology in the realm of drug delivery, offering targeted and efficient therapeutic interventions. Despite their scientific promise, the translation of nanocarriers from bench to bedside is fraught with challenges. These challenges span across regulatory, commercial, ethical, and technical dimensions. This review aims to provide a comprehensive overview of the mechanisms, efficacy, and challenges associated with nanocarriers in drug delivery. It also delves into the ethical considerations and future prospects of these advanced systems. The article concludes that while nanocarriers hold significant promise, a multi-faceted approach involving academia, industry, and regulatory bodies is essential for their successful clinical translation and commercialization.

Keywords- Nanocarriers, Drug Delivery, Regulatory Challenges, Ethical Considerations, Clinical Translation, Commercialization, Targeted Therapy, Bioavailability, Healthcare Disparities.

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

*Corresponding Author- khannaamit90@gmail.com

Update: Received on 20/05/2023; Accepted; 24/05/2023, Published on; 28/05/2023

Introduction

The field of pharmaceutics has witnessed a paradigm shift with the advent of nanotechnology, particularly in the realm of drug delivery systems. Nanocarriers have emerged as a revolutionary approach to targeted drug delivery, offering unprecedented advantages in terms of bioavailability, therapeutic efficacy, and reduced side effects. This review aims to provide a comprehensive overview of the advancements in nanocarriers for targeted drug delivery, focusing on their design, applications, and challenges in clinical translation.

Design and Applications

The design of nanocarriers has evolved significantly over the years, incorporating various materials and technologies to enhance their drug-loading capacity and release kinetics. Recent advancements have seen the development of nucleic acid nanocarriers that offer controlled drug delivery, thereby improving therapeutic outcomes (Mosley et al., 2023). These nanocarriers have found applications across a wide range of medical fields. For instance, in cardiovascular medicine, stents and balloons coated with drug-loaded nanocarriers have shown promise in reducing restenosis and improving patient outcomes (Ng et al., 2022).

Therapeutic Efficacy

The therapeutic efficacy of drugs can be significantly enhanced when delivered through nanocarriers. For example, cisplatin, a widely used chemotherapeutic agent, has been reformulated using nanotechnology to improve its bioavailability and reduce its toxicity (Farooq et al., 2019). Moreover, nanocarriers have also been employed in dermatological treatments, where herbal formulations have been encapsulated to improve their stability and skin penetration (Shree et al., 2022).

Biocompatibility and Safety

Biocompatibility is a critical factor in the design of nanocarriers. Recent studies have explored the use of cysteine-based biomaterials as drug nanocarriers, which offer the advantage of being biocompatible and biodegradable (Meng et al., 2020). However, the safety of these nanocarriers still remains a topic of ongoing research, especially concerning their long-term effects and potential for bioaccumulation.

Despite the promising advancements, several challenges impede the clinical translation of nanocarriers. These include issues related to scale-up, regulatory approval, and patient acceptance. The field is still in its nascent stage, requiring further research and development to address these challenges (Vandamme, 2008).

Nanocarriers in Cancer Therapy: Mechanisms, Efficacy, and Challenges

Mechanisms of Action

Nanocarriers have been extensively studied for their potential in cancer therapy, particularly for their ability to deliver therapeutic agents directly to tumor sites. One of the most promising mechanisms is the pH-responsive release of drugs, which takes advantage of the acidic tumor microenvironment to trigger the release of the encapsulated therapeutic agents (AlSawaftah et al., 2022). This pH-responsive behavior is not only innovative but also significantly enhances the therapeutic index of anticancer drugs.

Efficacy in Various Cancer Types

The efficacy of nanocarriers in cancer therapy has been demonstrated across a range of cancer types. For instance, lipid-based nanocarriers have shown promise in the delivery of chemotherapeutic agents, improving their bioavailability and reducing systemic toxicity (Estanqueiro et al., 2017). In lung cancer, gelatin-based nanocarriers have been employed for the pulmonary delivery of methotrexate, resulting in enhanced therapeutic outcomes (Abdelrady et al., 2019). Moreover, magnetic-driven nanocarriers have been developed for pH-responsive doxorubicin release, showing potential in targeted cancer therapy (Nogueira et al., 2020).

Challenges in Clinical Translation

Despite the promising in vitro and in vivo results, the clinical translation of nanocarriers faces several challenges. One of the primary concerns is the reduction-sensitive behavior of some polymeric nanocarriers, which can lead to premature drug release and reduced therapeutic efficacy (Deng et al., 2015). Additionally, the scale-up of nanocarrier production for clinical applications remains a significant hurdle, often requiring complex and costly manufacturing processes (Huyan et al., 2020).

Future Directions

The future of nanocarriers in cancer therapy looks promising but requires concerted efforts to overcome existing challenges. Innovations in the design of nanocarriers, such as dendrimer-based systems, offer new avenues for the delivery of nucleic acids and other macromolecular drugs (Palmerston Mendes et al., 2017). Furthermore, advances in near-infrared light-controlled release mechanisms open up new possibilities for spatiotemporal control of drug delivery (Guo & You, 2017).

Regulatory and Commercial Aspects of Nanocarriers in Drug Delivery

Regulatory Challenges

The regulatory landscape for nanocarriers in drug delivery is complex and evolving. While the potential for targeted therapy and reduced side effects is promising, regulatory agencies such as the FDA and EMA have stringent requirements for the approval of nanomedicines. These requirements often include exhaustive preclinical and clinical studies to demonstrate the safety, efficacy, and pharmacokinetics of the nanocarrier systems. The need for specialized assays to characterize nanomaterials adds another layer of complexity to the regulatory approval process (Date et al., 2012).

Intellectual Property and Market Access

Intellectual property rights are a critical aspect of the commercialization of nanocarriers. Patents provide a competitive edge but also come with challenges such as the need for extensive documentation and the risk of infringement. Market access is another hurdle, as the high cost of nanomedicines may limit their availability to a broader patient population. Strategies such as public-private partnerships and risk-sharing agreements can be employed to facilitate market access (Khot et al., 2020).

Scale-up and Manufacturing

The scale-up of nanocarrier production from laboratory to industrial scale is a significant challenge. The complexity of nanocarrier systems often requires specialized manufacturing processes, which can be both time-consuming and costly. Ensuring the reproducibility and quality of nanocarriers at a large scale is crucial for their commercial success (Banerjee & Pillai, 2019).

Future Prospects

The future of nanocarriers in drug delivery is promising but requires a multi-faceted approach to overcome existing challenges. Innovations in nanotechnology, coupled with strategic collaborations between academia, industry, and regulatory bodies, can accelerate the clinical translation and commercialization of nanocarriers. As the field matures, it is expected that regulatory frameworks will evolve to facilitate the approval and market entry of these advanced drug delivery systems.

Ethical Considerations in the Development and Application of Nanocarriers for Drug Delivery

Ethical Dimensions in Research and Development

The ethical considerations in the development and application of nanocarriers for drug delivery are multifaceted and extend beyond the realms of science and technology. Researchers and research trainees in the field of new technologies have varying perspectives on the acceptability of nanocarriers, influenced by their disciplinary cultures. These perspectives can significantly impact the ethical considerations surrounding the development and clinical application of nanocarriers (Chenel et al., 2015a).

Informed Consent and Autonomy

One of the critical ethical considerations is the principle of informed consent. Given the complexity of nanocarrier systems, ensuring that patients fully understand the risks and benefits associated with these therapies is paramount. The principle of autonomy mandates that patients should have the freedom to make informed decisions about their treatment options, which becomes particularly challenging given the complex nature of nanocarrier-based therapies.

Social and Economic Implications

The social and economic implications of nanocarrier technologies also warrant ethical scrutiny. The high cost of developing and manufacturing these advanced drug delivery systems may limit their accessibility, potentially exacerbating existing healthcare disparities. Ethical frameworks must be developed to ensure equitable access to these potentially life-saving technologies.

Ethical Oversight and Governance

The rapid advancements in nanocarrier technologies necessitate robust ethical oversight and governance mechanisms. Ethical review boards and regulatory agencies must be equipped with the expertise to evaluate the ethical dimensions of these technologies, including potential long-term effects that may not yet be fully understood (Chenel et al., 2015b).

Conclusion

The advent of nanocarriers in drug delivery has opened new avenues for targeted and efficient therapeutic interventions. These nanoscale systems have shown promise in enhancing the bioavailability of drugs, reducing systemic toxicity, and improving patient compliance. However, the journey from bench to bedside is fraught with challenges, ranging from scientific and technical hurdles to ethical and regulatory complexities (Nishiyama & Kataoka, 2006).

The regulatory landscape is particularly intricate, requiring exhaustive preclinical and clinical studies to ensure the safety and efficacy of these nanocarriers. Intellectual property rights and market access further complicate the commercial viability of these systems. The high cost of development and manufacturing could potentially limit the accessibility of these advanced drug delivery systems, raising ethical concerns about equitable access (Durak et al., 2020).

Moreover, the ethical dimensions of nanocarrier technologies are complex and multifaceted, encompassing issues such as informed consent, social implications, and governance. Ethical frameworks and robust oversight mechanisms are essential to guide the responsible development and application of these technologies (Sönksen et al., 2022).

Despite these challenges, the future of nanocarriers in drug delivery remains promising. Innovations in nanotechnology, coupled with strategic collaborations between academia, industry, and regulatory bodies, are likely to accelerate the clinical translation and commercialization of these systems. As the field matures, it is anticipated that regulatory frameworks will evolve to facilitate the approval and market entry of these advanced drug delivery systems, thereby fulfilling their promise in revolutionizing healthcare (Li et al., 2023).

References

1. Mosley, R. J., Rucci, B., & Byrne, M. E. (2023). Recent advancements in design of nucleic acid nanocarriers for controlled drug delivery. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 11(10), 2078–2094.
2. Ng, J. C. K., Toong, D. W. Y., Ow, V., Chaw, S. Y., Toh, H., Wong, P. E. H., Venkatraman, S., Chong, T. T., Tan, L. P., Huang, Y. Y., & Ang, H. Y. (2022). Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation. Nanomedicine (London, England), 17(5), 325–347.
3. Farooq, M. A., Aquib, M., Farooq, A., Haleem Khan, D., Joelle Maviah, M. B., Sied Filli, M., Kesse, S., Boakye-Yiadom, K. O., Mavlyanova, R., Parveen, A., & Wang, B. (2019). Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 1674–1692.
4. Shree, D., Patra, C. N., & Sahoo, B. M. (2022). Novel herbal nanocarriers for treatment of dermatological disorders. Pharmaceutical Nanotechnology, 10(4), 246–256.
5. Meng, Y., Han, S., Gu, Z., & Wu, J. (2020). Cysteine‐based biomaterials as drug nanocarriers. Advanced Therapeutics, 3(5), 1900142.
6. Vandamme. (2008). Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International Journal of Nanomedicine, 1.
7. AlSawaftah, N. M., Awad, N. S., Pitt, W. G., & Husseini, G. A. (2022). PH-responsive nanocarriers in cancer therapy. Polymers, 14(5), 936.
8. Huyan, T., Li, H., Peng, H., Chen, J., Yang, R., Zhang, W., & Li, Q. (2020). Extracellular vesicles – advanced nanocarriers in cancer therapy: Progress and achievements. International Journal of Nanomedicine, 15, 6485–6502.
9. Deng, B., Ma, P., & Xie, Y. (2015). Reduction-sensitive polymeric nanocarriers in cancer therapy: a comprehensive review. Nanoscale, 7(30), 12773–12795.
10. Estanqueiro, M., Amaral, M. H., & Sousa Lobo, J. M. (2017). Lipid-based nanocarriers in cancer therapy. In Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics (pp. 51–66). Elsevier.
11. Abdelrady, H., Hathout, R. M., Osman, R., Saleem, I., & Mortada, N. D. (2019). Exploiting gelatin nanocarriers in the pulmonary delivery of methotrexate for lung cancer therapy. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 133, 115–126.
12. Nogueira, J., Soares, S. F., Amorim, C. O., Amaral, J. S., Silva, C., Martel, F., Trindade, T., & Daniel-da-Silva, A. L. (2020). Magnetic driven nanocarriers for pH-responsive doxorubicin release in cancer therapy. Molecules (Basel, Switzerland), 25(2), 333.
13. Palmerston Mendes, L., Pan, J., & Torchilin, V. P. (2017). Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules (Basel, Switzerland), 22(9).
14. Guo, X., & You, J. (2017). Near infrared light-controlled therapeutic molecules release of nanocarriers in cancer therapy. Journal of Pharmaceutical Investigation, 47(4), 297–316.
15. Date, A. A., Patil, R. R., Panicucci, R., Souto, E. B., & Lee, R. W. (2012). Translating nanotechnology from bench to pharmaceutical market: barriers, success, and promises. Journal of Drug Delivery, 2012, 678910.
16. Khot, S., Rawal, S. U., & Patel, M. M. (2020). Theranostics Nanoformulations: Merging Diagnostics and Nanotherapeutics. In Nanoformulations in Human Health (pp. 73–91). Springer International Publishing.
17. Banerjee, S., & Pillai, J. (2019). Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs. Expert Opinion on Drug Metabolism & Toxicology, 15(6), 499–515.
18. Chenel, V., Boissy, P., Cloarec, J.-P., & Patenaude, J. (2015a). Effects of disciplinary cultures of researchers and research trainees on the acceptability of nanocarriers for drug delivery in different contexts of use: a mixed-methods study. Journal of Nanoparticle Research: An Interdisciplinary Forum for Nanoscale Science and Technology, 17(4), 186.
19. Chenel, V., Boissy, P., Cloarec, J.-P., & Patenaude, J. (2015b). Analyses of acceptability judgments made toward the use of nanocarrier-based targeted drug delivery: Interviews with researchers and research trainees in the field of new technologies. Nanoethics, 9(3), 199–215.
20. Nishiyama, N., & Kataoka, K. (2006). Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacology & Therapeutics, 112(3), 630–648.
21. Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A. (2020). Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials (Basel, Switzerland), 10(6), 1191.
22. Sönksen, M., Kerl, K., & Bunzen, H. (2022). Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Medicinal Research Reviews, 42(1), 374–398.
23. Li, S., Chen, L., & Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. Journal of Nanobiotechnology, 21(1), 232.